Oxford Spin-Out OMass Just Raised $298 Million: What It Means for EU Startups

Jan de Vries · 2026-10-16

OMass Therapeutics, a UK biotech spun out of Oxford University, just closed an oversubscribed $298 million (€275 million) Series C round. That's a lot of money for a company most people have never heard of. But it's a signal worth paying attention to, especially if you're watching the European startup scene. The round was co-led by Bain Capital Life Sciences, Forbion, and Novo Holdings. Janus Henderson Investors, SV Health Investors, and Jefferson Life Sciences also joined in. And every existing investor participated, including Syncona, Oxford Science Enterprises, GV, Northpond Ventures, Sanofi Ventures, British Business Bank, and the University of Oxford itself. So why does this matter beyond the headline number? ### A Big Bet on Hard Science OMass isn't your typical app or SaaS startup. They're developing small molecule therapeutics against targets that have historically been tough to drug. Their proprietary OdyssION platform combines native mass spectrometry, novel biochemistry, and custom chemistry to study drug targets in their native environments. Think of it like studying animals in the wild instead of a zoo—you get a more accurate picture of how things actually behave. The lead program, OMS1620, is a potential best-in-class MC2 receptor antagonist heading into Phase 2 trials for congenital adrenal hyperplasia (CAH) and ACTH-dependent Cushing's syndrome. If that sounds complex, it is. But it's exactly the kind of deep tech that Europe has been trying to nurture. ### The European Funding Landscape Is Heating Up OMass' round isn't an isolated case. In 2026 alone, several European therapeutics startups have raised significant rounds: - **Bionyra Pharma** (France) – $155 million for inflammatory disease treatments - **Breye Therapeutics** (Denmark) – $73 million for oral small-molecule pipeline - **STORM Therapeutics** (UK) – $51 million - **Microbiotica** (UK) – $45 million - **Mironid** (UK) – $43 million - **Alchemab Therapeutics** (UK) – $32 million - **Laigo Bio** (Netherlands) – $6 million Together, these deals add up to roughly $406 million in new financing during 2026—and that's before you include OMass' $298 million. With OMass, the total jumps to over $700 million. > "This financing comes at an exciting point in OMass' evolution as we advance OMS1620 into the clinic," says Ros Deegan, CEO of OMass Therapeutics. "With the backing of an outstanding group of new and existing investors, we are entering our next phase of growth with the resources to translate that progress into a portfolio of clinically differentiated medicines for patients." ### What This Means for Founders and Investors The takeaway here isn't just that one company raised a lot of money. It's that European deep tech and biotech are attracting serious capital from top-tier global investors. Bain, Novo Holdings, and Forbion don't write checks like this unless they see real potential. For founders, it's a reminder that building something scientifically rigorous can pay off—even if it takes years. For investors, it's a signal that the European ecosystem is maturing. And for everyone else, it's a glimpse into the kind of innovation that's happening in labs across the continent. OMass was founded in 2016 as a spin-out from Professor Dame Carol Robinson's lab at the University of Oxford. That's seven years of research and development before this round. It's a long game, but one that could eventually lead to new treatments for patients with significant unmet needs. So next time you hear about a European startup raising millions, don't just scroll past. Look at what they're building. It might be the next big thing in medicine.